Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 14/20 | 0.40 |
| ▸ | CA2 | P00918 | 14/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15508735 | 0.95 | BLM (0.45) | TDP1BLMPMP22HSD17B10CA1 | |
| SCHEMBL16995569 | 0.95 | BLM (0.45) | TDP1BLMPMP22HSD17B10CA1 | |
| SCHEMBL15508694 | 0.95 | TDP1 (0.46) | TDP1BLMPMP22HSD17B10CA1 | |
| SCHEMBL15508687 | 0.90 | BLM (0.50) | TDP1BLMPMP22HSD17B10CA1 | |
| SCHEMBL15508757 | 0.89 | CA1 (0.42) | TDP1BLMPMP22HSD17B10CA1 | |
| SCHEMBL24297332 | 0.86 | BLM (0.57) | TDP1BLMPMP22HSD17B10CA1 | |
| SCHEMBL23199547 | 0.86 | BLM (0.57) | TDP1BLMPMP22HSD17B10CA1 | |
| SCHEMBL15508749 | 0.86 | BLM (0.56) | TDP1BLMPMP22HSD17B10CA1 | |
| SCHEMBL16995566 | 0.85 | TDP1 (0.46) | TDP1CA1CA2MEN1GAA | |
| SCHEMBL16995780 | 0.85 | TDP1 (0.40) | TDP1CA1CA2MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359392-B2 | Dendrimer scaffolds for pharmaceutical use | VICTORIA LINK LIMITED (NZ) | 2016-06-07 | — | — | US | disclosed |
| US-20160145287-A2 | Dendrimer Scaffolds for Pharmaceutical Use | VICTORIA LINK LIMITED (NZ) | 2016-05-26 | — | — | US | disclosed |
| US-20150225439-A1 | Dendrimer Scaffolds for Pharmaceutical Use | VICTORIA LINK LTD (NZ) | 2015-08-13 | — | — | US | disclosed |
| WO-2014038963-A1 | DENDRIMER SCAFFOLDS FOR PHARMACEUTICAL USE | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225439-A1 | Dendrimer Scaffolds for Pharmaceutical Use | CD38, ADCYAP1R1, PIGO | TDP1 2465/4885BLM 1321/4885PMP22 3480/4885 |
| US-20160145287-A2 | Dendrimer Scaffolds for Pharmaceutical Use | CD38, ADCYAP1R1, PIGO | TDP1 2465/4885BLM 1321/4885PMP22 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.